You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

https://doi.org/10.1136/jitc-2021-003149corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Qin H, Yang L, Chukinas JA, et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J ImmunoTher Cancer 2021;9:e003149. doi: 10.1136/jitc-2021-003149

    This article has been corrected since it was first published. Middle initials have been added to author names ‘Nirali N Shah’ and ‘Naomi A Taylor’.